AEGIS-II
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
- Stadium
- klaar
- Middel
- CSL112
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 31 december 2018
- Last Patient In
- 18 november 2022
- Last Patient Last Visit
- 17 november 2023
National Lead
prof. dr. J.H. Cornel
Cardioloog
Studiedirecteur
drs. B.J.B. Hamer
Cardioloog
Contact Kantoor
